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Reveals Exceptions to Rules Governing Alloreactivity
Dianne De Santis,1,2 Bree A. Foley,1 Elisabeth John,2 David Senitzer,3 Frank T. Christiansen,1,2
Campbell S. Witt1,2Alloreactive NK cells lyse target cells lacking self-HLA-C or the HLA-B-Bw4 epitope. Prior to haploidentical
stem cell transplants, donor alloreactivity toward the patient is evaluated by natural killer (NK) cloning
followed by testing of the clones in the 51Cr-release assay. As only a few percent of NK clones are alloreactive,
a large number of NK clones must be established and evaluated. This approach is laborious and time consum-
ing, with a complete evaluation taking up to 6weeks.We developed a flow cytometry-based cytotoxicity assay
utilizing CD107a expression on 12-day polyclonally expandedNK cells and showed thatNK alloreactivityme-
diated by inhibitory and activating KIR can be detected bymeasuring CD107a expression following incubation
with targets lacking the appropriate class I epitope. The percentage of alloreactive NK cells varied greatly be-
tween individuals andwas easily estimated by theCD107a assay. For each epitope (C1, C2, Bw4), donorswere
found who did not have alloreactivity, although alloreactivity was predicted by the current rules thought to
govern alloreactivity. The data emphasize the importance of demonstrating alloreactivity in a functional assay.
Biol Blood Marrow Transplant 16: 179-191 (2010)  2010 Elsevier Inc. All rights reserved.KEY WORDS: Human, Natural Killer Cells, Transplantation, MHCINTRODUCTION
Natural Killer (NK) cell alloreactivity can be
exploited in haploidentical hematopoietic stem cell
transplantation (HSCT) to prevent leukemia relapse,
rejection, and graft-versus-host disease (GVHD) [1],
and is also being investigated for treatment of leukemia
using nonmyeloablative (NMA) regimens [2].However,
confirming donor alloreactivity is complex and time
consuming.
Lysis byNK cells is inhibited when their inhibitory
receptors recognize class I HLA molecules on
potential target cells. A particular class of inhibitory1School of Pathology and Laboratory Medicine, Univer-
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6/j.bbmt.2009.10.026receptor known as killer cell immunoglobulin-like
(KIR) receptors recognizes allelic epitopes on HLA-
C and HLA-B molecules [3,4]. All HLA-C alleles can
be divided into 2 groups, based on their amino acid at
position 80 [5]. C1-group alleles have an asparagine
at position 80 and are recognized by the inhibitory
KIR receptors KIR2DL2 and KIR2DL3. C2-group
alleles have a lysine at position 80 and are recognized
by KIR2DL1 [3]. HLA-B alleles can also be divided
into 2 groups, Bw4 and Bw6, based on the amino acids
77-83. KIR3DL1 recognizes HLA-B and some
HLA-A alleles with the Bw4 epitope [4]. During devel-
opment in individuals who lack one of these allelic
epitopes, NK cells expressing the inhibitory KIR for
that epitope as their only inhibitory receptor fail to be-
come armed for cytotoxicity [6,7], thereby preventing
the generation of autoreactive NK cells.
To a large extent, donor NK alloreactivity toward
a recipient can be predicted if the recipient lacks one
of the C1, C2, or Bw4 epitopes that is present in the
donor. However, this assumes that (1) all HLA-C and
HLA-B alleles interact with the appropriate inhibitory
KIRreceptors aspredictedby thepresenceof the relevant
amino acids, and (2) that all alleles of the inhibitoryKIR
receptors interact the samewaywith theHLAepitopes.
These assumptions are not always valid. HLA-B13, al-
though known to have the Bw4 epitope, does not inter-
act with KIR3DL1 [8], whereas KIR2DL2 and
KIR2DL3 may interact with both C1- and C2-type
HLA-C alleles [9-11]. Failure of a particular179
Table 1. HLATypes andKIR Epitopes of BLCLUsed as Target
Cells Used in the CD107a Assay
KIR Epitopes
Identifier C1 C2 BW4 HLA-A HLA-B HLA-C
721.221 2 2 2
‘‘All’’ + + + 01, 03 27, 44 01, 04
‘‘C12’’ 2 + + 02 57 06
‘‘C22’’ + 2 + 33 58 03
‘‘Bw42’’ + + 2 03, 11 07, 35 04, 07
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dicted will result in failure of the predicted NK
alloreactivity to develop in potential donors or may
result in a recipient’s cells unexpectedly being resistant
to lysis by donor NK cells. Moreover, there is increas-
ing evidence that activating receptors, particularly
KIR2DS1, interacting with their ligands, may mediate
allorecognition and further complicate the rules
[11-13]. As there has been no comprehensive study to
determine which allelic variants of the KIR alleles in-
teract with the different HLA alleles, it is not possible
to reliably predict alloreactivity from HLA types and
KIR genotype and, therefore, a functional assay is de-
sirable.
Functional demonstration of donorNK alloreactiv-
ity toward patient target cells is currently confirmed by
generating donor NK cell clones and testing the ability
of theseNKclones to lyse a patient’s cells in the 51Cr-re-
lease cytotoxicity assay [1]. As only a few percent of NK
cells are alloreactive [14], it is necessary to generate and
test at least 200 NK clones to be sure of detecting low-
frequency alloreactive NK cells. This process is labor-
intensive, often requiring 4 to 6 weeks to complete,
and is thus a significant deterrent for centers that might
otherwise exploit alloreactive NK cells. We have there-
fore developed a flow cytometric, CD107a-based assay
capableof detectingNKcell alloreactivity in14days.Al-
though the results of this assay correlate well with pre-
dictions of alloreactivity based on HLA types and KIR
genotype, there were exceptions.MATERIALS AND METHODS
NK Cells
Blood was obtained from 42 consenting laboratory
and volunteer blood donors. All were typed for
HLA-A, -B, and -C alleles (Table 1, SupplementaryTable 2. Antibodies Used to Identify Potentially Alloreactive NK C
Antibody Label Clone Dilut
CD158a APC EB6B 1/25
CD158b APC GL183 1/25
CD158a PE HP-3E4 1/10
CD158b PE CH-L 1/10
CD158e PE DX9 1/10
CD56 PE-Cy7 B159 1/40data) and genotyped for the presence or absence of 10
KIR genes (Table 2, Supplementary data). NK cells
were purified by ficoll centrifugation with RosetteSep
(StemCell Technologies, Vancouver, Canada). Purified
polyclonal NK cells were expanded by culturing with
irradiated allogeneic feeder cells (peripheral bloodmono-
nuclear cells [PBMC] pooled from at least 5 donors) at
a 1:10 ratio for 12 days with 200 IU/mL IL-2 (Chiron,
Emeryville, CA) replacing the NK medium every 2 to
3 days. Before use in the CD107a assay, 12-day cultured
polyclonal NK cells were cultured at 1  106/mL for a
further 48 hours with 400 IU/mL IL-2. In some experi-
ments, freshly isolated PBMC cultured for 48 hours in
the presence of 1000 IU/mL IL-2, but without feeder
cells, were used in the CD107a assay.
Target Cells
B lymphoblastoid cell line (BLCL) with various
combinations of C1, C2, or Bw4 epitopes, were used
as target cells (Table 1). All cells were cultured in
RPMI-1640 (Invitrogen Carlsbad, CA), with 10%
heat-inactivated fetal calf serum (FCS) (Thermo-
Trace, Melbourne Australia).
KIR Genotyping and HLATyping
HLA-typing of NK donors and target cells was
performed by DNA sequencing of exons 2 and 3.
KIR genotyping of donors was performed using
amultiplex PCR-sequence-specific primers (SSP) [15].
CD107a Cytotoxicity Assay
The expression of CD107a on the membrane has
been shown to be a good correlate of target cell lysis
in the 51Cr-release assay [16], and was therefore used
as the marker for NK-mediated cytotoxicity; 105 poly-
clonally expanded NK cells or 106 IL-2 activated
PBMC were incubated at 37C with 105 BLCL target
cells in a final volume of 200 mL in a 96-well round-
bottom plate to which 5 mL of anti-CD107a-FITC
(BD Biosciences, Franklin Lakes, NJ) was added. After
1-hour incubation, 6 mg/mL monensin (BD Golgi-
Stop BD Biosciences) was added, the cells incubated
a further 5 hours, and then resuspended in 50 mL of an
antibody cocktail containing anti-CD56-PECy7 (BD
Biosciences) and the appropriate conjugated KIR anti-
bodies (Table 2). Duplicate tubes were analyzed on
a BD FACSCanto flow cytometer using BDells
ion KIR Reactivity Supplier
2DL1, 2DS1 Beckman Coulter
2DL2, 2DL3, 2DS2 Beckman Coulter
2DL1, 2DS1 BD Biosciences
2DL2, 2DL3, 2DS2 BD Biosciences
3DL1 BD Biosciences
BD Biosciences
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forward and side scatter (SSC) to identify lymphocytes.
A bivariate plot of CD56 versus SSC was used to ac-
quire at least 10,000 CD561 cells. CD561 cells were
further gated to identify cells expressing the KIR phe-
notype of interest, for example, CD158a1 or
CD158a1/158b2. The cells of interest were then ana-
lyzed in a bivariate plot showing the receptor of inter-
est (eg, CD158a) on one axis and CD107a on the other
axis to determine the percentage of cells with the KIR
phenotype of interest that were also CD107a1. Not all
donors were tested in all assays. Those tested in each
assay are shown in Table 1, Supplementary data.
Only donors with KIR3DL1 expression confirmed
by flow cytometry were tested for HLA-Bw4-depen-
dent NK cells.Statistical Analysis
CD107a expression was analyzed as the mean of
duplicate wells. The significance of differences in the
number of CD107a-positive cells between NK donors
of different genotypes in Figures 3 and 4 were tested by
Fisher’s exact test after setting a cutoff that gave great-
est distinction between genotypes.RESULTS
NK cells identified as potentially alloreactive
by virtue of their KIR receptor expression
upregulate CD107a in response to targets
lacking the relevant HLA epitope
Initiallyweexamined the feasibilityofusingCD107a
expression to detect alloreactive NK cells. NK cells
capable of lysing targets lacking the C1 epitope (C1-
dependent) would be expected to express KIR2DL2 or
KIR2DL3 (CD158b1) in the absenceof other inhibitory
receptors, particularly KIR2DL1 (CD158a2). There-
fore, CD107a expression was examined on such ‘‘poten-
tially C1-dependent NK cells.’’ Similarly, NK cells
capable of expressing CD107a in the presence of targets
lacking the C2 epitope (C2-dependent) or the Bw4
epitope (Bw4-dependent) would be expected to express
only KIR2DL1 (CD158a1) in the absence of other in-
hibitory receptors (Cd158b2) or KIR3DL1 (CD158e1)
in the absence of other inhibitory receptors (CD158a2,
CD158b2), respectively.
Twelve-day polyclonally expanded NK cells from
a donor whose HLA type included the C1, C2, and
Bw4 epitopes were incubated with different BLCL tar-
gets each lacking just one of the C1, C2, or Bw4 epi-
topes (see Table 1 for the HLA types of the C12,
C22, Bw42 targets) or with a target expressing all epi-
topes (All) or with the class I-negative 721.221 BLCL
(721.221) or without any target present. NK cells that
were potentially alloreactive toward targets lackinga single epitope (ie, potentially C2-dependent, C1-
dependent, or Bw4-dependent) were gated on the basis
of their KIR expression as described earlier. The
results of one representative experiment are shown in
Figure 1. In the absence of a target cell, #1% of all 3
potentially alloreactive NK subsets expressed
CD107a (Figure 1A). Only a small proportion
(1.6%-2.4%) of potentially alloreactive NK cells
were CD107a1when incubated with the negative con-
trol target expressing all (C1, C2, Bw4) epitopes
(Figure 1B), whereas the majority (57%-67%) were
positive when incubated with the positive control tar-
get 721.221. As shown in Figure 1D-F, potentially al-
loreactiveNK cells expressed CD107a when incubated
with targets lacking the relevant inhibitory ligand, but
few expressed CD107a when incubated with targets
lacking irrelevant inhibitory ligand. For example,
Figure 1E shows that 10.5% of potentially C2-depen-
dent NK cells (CD158a1, CD158b2) expressed
CD107a when incubated with the C22 (C1/1) target
compared to only 4.4% (Figure 1D) and 2.2%
(Figure 1F) when incubated with other C21 targets
(C12 target and Bw42 target, respectively); propor-
tions that are similar to those when incubated with
the target bearing all epitopes (1.6%; Figure 1B). Sim-
ilar findings are shown for potentially C1-dependent
NK cells in the presence of the C12 (C2/2) target
and potentially Bw4-dependent NK cells in the pres-
ence of the Bw42 (Bw6/6) target. Thus, for an individ-
ual with all three epitopes, CD107a was expressed on
the appropriate population of NK cells when incu-
bated with targets lacking the relevant epitope.
We next examined the influence of theNK donor’s
HLA epitopes on the presence of alloreactiveNK cells.
As shown in Figure 2, alloreactive NK cells could only
be identified if the missing epitope on the target is
a self-epitope. Polyclonally expanded NK cells from
a C11 (C1/1) and a C12 (C2/2) donor were incubated
with a negative control target with all epitopes (‘‘All,’’
Table 1), with a positive control target 721.221, or
a target lacking only C1 (‘‘C12’’). Twenty-two percent
of potentially C1-dependent NK cells from the C11
donor expressed CD107a in response to the C12 tar-
get (Figure 2.A3), whereas this was true of only 2.8%
of such NK cells from the C12 donor (Figure 2.A6).
Potentially C1-dependent NK cells from both donors
expressed CD107a in response to the class I HLA neg-
ative 721.221 target cell equally (41.4% versus 41.3%;
Figure 2.A2 and A5), indicating that these cells from
both donors were armed for cytotoxicity. The inability
of these armed cells in the C12 donor to kill the C12
(C2/C2) target suggests these potentiallyC1-dependent
cells must express another inhibitory receptor in C12
donors. Similar data is shown in relation to C2
(Figure 2.B1-6) and Bw4 (Figure 2.C1-6). However,
in the case of the Bw4 negative donor (Figure 2 C4-6),
it should be noted that whereas a relatively high
Figure 1. NK cells identified as potentially alloreactive on the basis of KIR receptor expression, express CD107a in response to target cells lacking the
appropriate epitope. Day 12, polyclonally expanded NK cells from a donor whose HLA type included the C1, C2, and Bw4 epitopes (donor 5, Table 1,
Supplementary data) were incubated for 6 hours with (A) no target cells (None); (B) a target expressing the C1, C2, Bw4 epitopes (All); (C) the class I
HLA bare cell line 721.221 (721.221); (D) a target expressing all epitopes except C1 (C12); (E) a target expressing all epitopes except C2 (C22); (F)
a target expressing all epitopes except Bw4 (Bw42) (see Table 1 for target cell details). NK cells were then stained with anti-KIR antibodies enabling the
identification of NK cells potentially alloreactive toward one or other epitope negative target and CD107a expression assessed. Cells were initially gated
for CD56 positivity and a second gate applied to include only those cells with the potentially alloreactive KIR phenotype. Potentially C2-dependent NK
cells (CD158a1, CD158b2) (left hand column of graphs) expressed CD107a in the presence of 721.221 and the C12 target. Potentially C1-dependent
NK cells (CD158a2, CD158b1) (center column of graphs) expressedCD107a in the presence of 721.221 and theC22 target. Potentially Bw4-dependent
NK cells (KIR3DL1(CD158e)1, CD158a2, CD158b2) (right-hand columnof graphs) expressedCD107a in the presence of 721.221 and the Bw42 target.
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ent NK cells were CD107a1 in response to the
Bw4- target, the sparse dot plots indicate that Bw4
negative donors have very low absolute numbers of
potentially KIR3DL1-dependent NK cells. This
fact will become important in subsequent analyses
(vide infra).Detection of NK Alloreactivity Is Critically
Dependent on the Analysis Method
To determine whether the CD107a assay could be
used to replace NK cloning and the 51Cr-release cyto-
toxicity assay, we asked whether the CD107a assay
could reliably detect the presence of alloreactive NK
cells as predicted by an individual’s HLA and KIR ge-
notype. The ability to detect NK cells alloreactive
against targets lacking a single epitope was examined
in a panel of 42 NK donors (HLA and KIR genotypes
provided in Tables 1 and 2, Supplementary data).
Day-12 polyclonally expanded NK cells isolated
from these donors were incubated alone, with the
HLA class I-negative 721.221 target, a target express-
ing all epitopes (‘‘All’’), and target cells lacking only C1
(‘‘C12’’), only C2 (‘‘C22’’), or only Bw4 (‘‘Bw42’’). The
percent of NK cells expressing CD107a when incu-
bated with each target (minus the percent positive in
the absence of a target) was plotted and is shown for
the C12, C22 , and Bw42 targets in Figure 3. If
CD107a expression occurs on NK cells only in re-
sponse to missing epitopes on the target, then a simple
analysis of the frequency of CD107a1 cells as a per-
centage of all NK cells (ie all C561 cells) should allow
the enumeration of alloreactive NK cells. Such an
analysis (Figure 3A) shows that this is only partially
true. For example, when incubated with a C22 target,
C21 donors (C1/C2 and C2/C2) tended to have more
C2-dependent CD107a1 cells than C22 donors (C1/
C1), but there was considerable overlap between the
two types of donor. Similar findings were evident for
C1-dependent and Bw4-dependent NK cells using
targets lacking the C1 or Bw4 epitope, respectively.
The lack of a clear distinction between donors with
and without predicted alloreactivity suggests that
NK receptors other than the inhibitory KIR may me-
diate CD107a expression in response to these BLCL
targets, thereby preventing detection of CD107a
expression only because of the missing HLA epitope.
In an attempt to minimize the effect of irrelevant
receptors we restricted the analysis to only NK cells
expressing the inhibitory KIR receptor relevant to
the missing epitope. As shown in Figure 3B, this ad-
justment resulted in little improvement in distinction
between donors with and without predicted alloreac-
tivity. We then further restricted the analysis of
CD107a expression to only those NK cells expressing
inhibitory KIR relevant to the missing epitope on thetarget cell and not expressing the other inhibitory
KIR (Figure 3C). This resulted in improved discrimi-
nation between donors with and without predicted
alloreactivity against C22 and C12 targets, but not
for Bw42 targets.
The analysis so far examined the percentage of
CD107a expression among cells identified as poten-
tially alloreactive without taking into account the fre-
quency of such cells as a proportion of all NK cells.
Figure 3D shows the percentage of all NK cells ex-
pressing the receptor phenotype of potentially allo-
reactive NK cells without reference to CD107a
expression. It can be seen that for many individuals,
these cells are infrequent. In particular, the percentage
of CD158a1, CD158b2 cells present in C1 homozy-
gous individuals (Figure 3D, left) and the percentage
of CD158e1, CD158a2, CD158b2 NK cells in Bw6
homozygous individuals (Figure 3D, right) was very
low, and therefore the estimates of the proportion of
these cells expressing CD107a, as plotted in
Figure 3C, may lack precision. We therefore plotted
the number of NK cells that expressed the relevant in-
hibitory KIR receptor and not other KIR (potentially
alloreactive) and that were CD107a1 as a percentage
of all NK cells (CD561 cells), on a linear (Figure 3E)
and log scale (Figure 3F). As shown, for NK donors
whose HLA epitopes would predict inability to gener-
ate alloreactive NK cells for that particular epitope,
these cells were invariably present at a frequency of
\1%, whereas in most individuals in whom alloreac-
tivity was predicted, such cells were present at a fre-
quency .1% (P \ .0001 for all comparisons of
number of CD107a1 cells in donors with the ligand
versus donors without the ligand).The CD107a Assay Can Be Used to Evaluate the
Rules of NK Allorecognition
Given that the CD107a assay usually detected ex-
pectedNK alloreactivity when the appropriate method
of analysis was used, we examined more closely the ap-
parent exceptions. As shown in Figure 3F (left), it can
be seen that all C22 (C1/1) NK donors had\1% (and
generally fewer than 0.1%) C2-dependent NK cells
when incubated with C22 targets. In contrast most
C21 donors (all but two C1/2 donors and all but two
C2/2 donors) had .1% such cells. The two C1/2 ex-
ceptions are actually replicate estimations for the
same individual (donor 4, Table 1, Supplementary
data) assayed on different days. By DNA sequencing,
this individual was shown to be homozygous for the
KIR2DL1*004 allele, which is found on some KIR-B
haplotypes, suggesting that the KIR2DL1*004 allele
may not interact with the C2 epitope. Although not
tested, it is unlikely that any other C21 donors had
KIR2DL1*004 as their only KIR2DL1 allele because
all other donors had KIR2DL3, which is present
Figure 2. CD107a expression in response to epitope negative targets is dependent on the HLA type of the NK cell donor. Day 12, polyclonally ex-
pandedNK cells from a C11 (C1/1) donor (donor 28 in Table 1, Supplementary data) and a C12 (C2/2) donor (donor 39 in Table 1, Supplementary data)
were incubated with target cells expressing all epitopes (‘‘All’’ in Table 1) (negative control) (A1 and A4), 721.221 (positive control) (A2 and A5) and
a C12 target (C12 in Table 1) (A3 and A6) for 6 hours. Potentially C1-dependent (CD158a2, CD158b1) NK cells were then examined for CD107a
expression. NK cells from the C11 (C1/1) donor expressed CD107a in the presence of 721.221 (A2) and the C1-target cell (A3), whereas NK cells
from the C12 (C2/2) donor only expressed CD107a in response to 721.221 (A5) and not the C12 target (A6). Similar data are shown for C21 (donor
4) and C22 (donor 41) donors (B1-B6) and for Bw41 (donor 42) and Bw42 (donor 28) donors (C1-C6).
184 Biol Blood Marrow Transplant 16:179-191, 2010D. De Santis et al.
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carry a KIR2DL1 allele other than KIR2DL1*004.
The two C12 donors (C2/2, donors 36, 37 in Table
1, Supplementary data) who had\1% CD107a1 NK
cells in the presence of the C22 target lacked the
KIR2DL1 gene and would therefore not be expected
to have such alloreactive NK cells.
All C12 (C2/2) donors had\2% C1-dependent
NK cells when incubated with C12 targets
(Figure 3F, middle) whereas, with one exception, all
C11 (C1/2 and C1/1) donors had .4% such cells.
The single exception (donor 10, Table 1, Supplemen-
tary data) cannot be explained by any of the current
rules for alloreactivity. This donor is homozygous
for KIR2DL3 gene and has both the KIR2DL3*001
and KIR2DL3*002 alleles. The donor’s C1 ligand is
HLA-Cw*07, which has been reported to be an effec-
tive KIR2DL2/3 ligand [17]. For reasons that are not
clear, this donor’s alloreactivity was heavily biased
towards the use of KIR2DL1 (data not shown).
All Bw42 (Bw6/6) NK donors had \1% Bw4-
dependent NK cells when incubated with the Bw42
target, whereas most Bw41 donors had.1% such cells
(Figure 3F, right). However, six Bw41 donors had
\1% Bw4-dependent NK cells. The lack of such cells
in these 6 donors could not be explained by homozy-
gosity for the nonexpressed allele of KIR3DL1
(KIR3DL1*004), as all donors were shown by flow cy-
tometry prior to testing to have NK cells expressing
KIR3DL1. The only Bw41 allele in three of these do-
nors was HLA-B13, consistent with our recent report
that HLA-B13, does not act as a ligand for KIR3DL1.
In a fourth donor, HLA-A24 was the only Bw41 allele,
suggesting that HLA-A24 may not always be an effec-
tive ligand for the arming of Bw4-dependent NK cells.
The reason for the low number of Bw4-dependent NK
cells in the remaining 2donors is unclear.One had both
HLA-B57 andHLA-A32 as Bw41 alleles and, although
one of this donor’s KIR3DL1 alleles was the non-
membrane expressed KIR3DL1*004, the other allele
was KIR3DL1*005, which is known to interact with
HLA-B57 [8]. The other donor had HLA-B44
(Bw41) and the KIR3DL1 alleles *001 and *007 and
it seems unlikely that neither of these alleles would
interact with HLA-B44. Although the frequency of
Bw4-dependentNKcells was low in these 6 exceptions,
5 of the 6 donors had between 0.4% and 1% Bw4-
dependent NK cells. This frequency was higher than
for any of the Bw42 (Bw6/6) donors, suggesting that
these individuals are capable of armingBw4-dependent
NK cells, but at very low frequencies and that the
CD107a assay can detect these low frequency cells.Detection of KIR2DS1-Mediated Alloreactivity
We next tested whether the CD107a assay could
detect KIR2DS1-activated alloreactive NK cells. We[13] and others [11,12] have shown that NK cells
mediating alloreactivity through KIR2DS1 can be
identified among CD158a1 (KIR2DS11), CD158b2
(KIR2DL22, KIR2DL32) cells, but only in C22
donors [13]. Although the frequency of NK cells with
this KIR phenotype varies greatly between donors, it
is worth noting that they are more frequent in C21 do-
nors; individuals in whom KIR2DS1-dependent NK
cells would not be expected (Figure 4A). This probably
reflects the fact that the majority of CD158a1 cells in
such individuals are KIR2DL11 rather than
KIR2DS11. As the percentage of such cells is so
much greater in C21 individuals than in C22 (C1/
C1) individuals, any CD107a expression among this
subset of cells that is unrelated to KIR2DS1-mediated
alloreactivity would therefore be likely to obscure the
detection of KIR2DS1-mediated CD107a expression.
Nevertheless, we initially used the analysis method
that best demonstrated alloreactivity of NK cells
controlled by inhibitory receptors. Figure 4B shows
the percentage of all CD561 NK cells that are
CD158a1, CD158b2, CD107a1 (the phenotype ex-
pected for KIR2DS1 controlled NK cells) after incuba-
tion with a C2 homozygous target. C22 donors had few
CD107a1 cells, and ifCD107a expressionwasmediated
through KIR2DS1, unexpectedly those with the
KIR2DS1 gene did not have higher numbers of
CD107a1 cells than those without KIR2DS1
(Figure 4B). Rather, the number of CD107a1 cells was
closely correlated with the proportion of all CD561
NK cells that were CD158a1, CD158b- (Figure 4A),
most of which are probably KIR2DL11 cells. Any
‘‘background’’ CD107a response among these cells
may be sufficiently large to obscure the low frequency
KIR2DS1-controlled cells. Figure 4C suggests that
this is indeed the case. When the number of CD107a1
cells is taken as a percentage of the total number of
CD158a1, CD158b2 cells (Figure 4C), then the influ-
ence of KIR2DS1 is evident. At least 14% of such cells
were CD107a1 among C22 (C1/1) donors who had
theKIR2DS1gene (those inwhomKIR2DS1-mediated
alloreactivitymight be expected),whereas allC22 (C1/1
homozygous)donorswithout theKIR2DS1geneand all
C21 donors, with a single exception, had \14%
CD107a positive cells (P\ .001). Similar trends were
observed for the C1/2 heterozygous target (data not
shown) although the proportion of CD107a1 cells was
lower with this target, consistent with our previous re-
port that C2 homozygous targets are more easily killed
byKIR2DS1 controlledNK cells than are C1/2 hetero-
zygous targets [13]. Taken together, these data suggest
CD107a expression can be used to detect KIR2DS1-
mediated NK allorecognition. However, the assay did
not distinguish between donors expected to have
KIR2DS1 controlled cells and donors not expected to
have KIR2DS1 controlled cells as clearly as was the
case for alloreactive cells controlled by inhibitory KIR.
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Figure 3. Appropriate analysis of CD107a data reveals alloreactivity that correlates well with alloreactivity predicted by HLA and KIR genetics. Day 12,
polyclonally expandedNK cells from different donors were incubated with target cells lacking a single epitope and CD107a expression was measured on
the NK cells. The heading at the top of each column indicates the target cell used (see Table 1) for the graphs in that column and, in brackets?, the ligand
potentially determining NK allorecognition. The total population of cells considered (denominator) is shown at the top of each graph. Each point rep-
resents the number of cells with the phenotype shown on the vertical axis as a percentage of the denominator. The HLA epitopes present in the NK cell
donors is shown at the bottom of the figure. The percentage of CD561 cells expressing CD107a (A), percentage of cells with inhibitory receptor rel-
evant tomissing epitope on target cells that are expressing CD107a (B), percentage of cells with inhibitory receptor relevant tomissing epitope on target
cells and lacking other inhibitory KIR that are expressing CD107a (C), percentage of cells with inhibitory receptor relevant to missing epitope on target
cells and lacking other inhibitory KIR (D), percentage of CD561 cells with inhibitory receptor relevant to missing epitope on target cells and lacking
other inhibitory KIR that are expressing CD107a (E); and the same data as in 3e but with vertical axis on log scale (F). Figure 3F shows that for NK
donors whose HLA type would predict inability to generate alloreactive NK cells for that particular epitope, CD107a1 cells were invariably present
at a frequency of\1%, whereas in most individuals in whom alloreactivity was predicted, such cells were present at a frequency .1% (P\.0001 for
all comparisons of number of CD107a1 cells in donors with the ligand versus donors without the ligand).
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As all assays were performed in duplicate tubes, the
CV was calculated for each NK donor whose fre-
quency of alloreactive NK cells was .1%. The mean
within-run CV for the estimate of C1-dependent,
C2-dependent, and Bw4-dependent alloreactive NK
cells was 5.9%, 13.4%, and 6.3%, respectively.Figure 4. Appropriate analysis of CD107a data results in good corre-
lation with KIR2DS1-mediated alloreactivity predicted by HLA and KIR
genetics. Day 12, polyclonally expanded NK cells from different donors
were incubated with target cells and CD107a expression was measured
on theNK cells. The heading at the top of each graph indicates the mem-
brane phenotype of NK cells analyzed (denominator). The HLA epitope
phenotype and presence or absence of the KIR2DS1 gene in the NK cell
donors is shown at the bottom of the figure. Each point represents for
each donor the number of cells with the phenotype shown on the ver-
tical axis as a percentage of the denominator. (A) Percentage of NK cells
CD158a1, CD158b2 without reference to CD107a expression and in
the absence of any target. (B) percentage of CD561 cells that are
CD158a1, CD158b2, and CD107a1 after incubation with a C12
(C21, Bw41) target. (C) Percentage of CD158a1, CD158b2 cells that
are CD107a1 after incubation with a C12 (C21, Bw41) target. Graph
(C) shows that the expected CD107a positivity is restricted to only
KIR2DS11, C22 donors (P \ .001 for %CD107a1 cells in the
KIR2DS11, C22 versus others).Freshly Isolated and IL-2-Activated NK Cells
Are Unsuitable for the CD107a Assay
The data before show that 12-day polyclonally ex-
panded NK cells can be used to detect NK cell allo-
reactivity. We also assessed whether freshly isolated
NK cells or PBMC activated with IL-2 in the absence
of feeder cells for 48 hours could be used to detect
NK cell alloreactivity in the CD107a assay. Very
few freshly isolated NK cells expressed CD107a in re-
sponse to BLCL targets, so these cells were not pur-
sued further (data not shown). PBMC from 4 donors
(donors 8, 18, 28, and 42) were activated with IL-2 for
48 hours and compared with 12-day cultured poly-
clonal NK cells from the same donors. Donors 8
and 28 and donors 18 and 42 were used to generate
C1 and Bw4-dependent NK cells, respectively, and
the proportion of each as a percentage of total
CD561 NK cells was determined as described in
Figure 3C. Whereas 12-day cultured NK cells were
used at an effector to target ratio of 1:1, the IL-2 ac-
tivated PBMC were used at an effector target ratio of
10:1 as NK cells generally represent only 10% of
PBMC.
The percentage of NK cells expressing CD107a in
the presence of BLCL targets was markedly decreased
in the IL-2activatedPBMCcompared to12-day cultured
NK cells (data not shown). For the two C1-dependent
NK cell donors, in the presence of the class I bare
target (721.221), 12% and 19% of NK cells in the
IL-2 activated PBMC expressed CD107a compared
to 59% and 31% of cultured NK cells. In the pres-
ence of the C12 target, only 2% and 0.6% of IL-2
activated NK cells in the PBMC were CD158b1,
CD158a2, and CD107a1 compared to 6% and
5.3% of cultured NK cells. A similar trend was
seen for the two Bw4-dependent NK cell donors.
In the presence of 721.221, 17% and 15% of IL-2
activated NK cells in the PBMC were CD107a1
compared to 73% and 20% of cultured NK cells.
In the presence of the Bw42 target, only 0.3% and
0.15% of IL-2 activated NK cells in the PBMC
were CD158e1, CD158a2, CD158b2, CD107a1
compared to 3.4% and 4.3% of cultured NK cells.
The low percentage of IL-2 activated NK cells in
the PBMC expressing CD107a suggested that it
would be difficult to establish a reproducible assay
using such cells.Role of NKG2A1NK Cells in the CD107a Assay
Because the ligand for NKG2A is the non-poly-
morphic HLA-E and because BLCL express HLA-E,
it might be expected that NK cells expressing
NKG2A would not be alloreactive. However, as we
have found alloreactive NK clones that express
NKG2A using the 51Cr-release assay (unpublished
data), we wondered whether such cells contributed to
the alloreactivity detected in the CD107a assay. We
therefore tested 2 donors for alloreactivity against
BLCL targets lacking only C2 (Figure 5A) or C1
(Figure 5B) and estimated the frequency of CD107a
cells with and without gating outNKG2A1 cells to de-
termine whether any alloreactive cells detected in this
Figure 5. NKG2A1 cells do not contribute significantly to the allo-
reactive subsets. Twelve -day polyclonally expanded NK cells from 2 do-
nors were incubated with target cells and CD107a expression assessed
either without (solid bars) or with (open bars) gating of NKG2A positive
cells. (A) The number of cells that were CD158a1, CD158b2, CD107a1
after incubation with a target lacking only ,C2 and (B) the number of cells
that were CD158b1, CD158a2, CD107a1 after incubation with a target
lacking only C1. The frequency of CD107a1 cells was unchanged by
NKG2A gating.
188 Biol Blood Marrow Transplant 16:179-191, 2010D. De Santis et al.assay expressedNKG2A. As shown in Figure 5, the fre-
quency of alloreactive cells was the same in 12-day pol-
yclonally expanded NK cultures whether NKG2A1
cells were gated out or not, suggesting that the alloreac-
tive cells detected in this assay do not express NKG2A.
Influence of 12-Day Culture on Frequency of
Alloreactive NK Cells
As freshly isolated NK cells did not up regulate
CD107a in response to BLCL targets, it was not possi-
ble to directly compare the frequency of functionally
alloreactive clones at day 0 and day 12 using the
CD107a assay. To determine whether 12 days in cul-
ture altered the frequency of potentially alloreactive
NKcells, the frequency ofNKcells with the potentially
alloreactive KIR phenotypes analyzed in the CD107a
assay was compared at day 0 and day 12. Figure 6 shows
that the frequency of cells with potential alloreactivity
tended to increase modestly if the donor was positive
for the relevant epitope anddecrease if the donor lacked
the epitope. The percentage of CD158a1 (Figure 6A)
and CD158a1,158b2 (Figure 6C) NK cells increased
in C21 donors (C1/2 heterozygotes) and decreased in
C22 donors (C1/1 homozygotes). The single C2 ho-
mozygous donor did not have the KIR2DL1 gene
and could not therefore be assessed. A tendency for
CD158b1 (Figure 6B) and CD158b1,158a2
(Figure 6D) cells to increase in C11 donors was also
apparent, although two C1/2 donors showed modest
decreases, and one C1/1 homozygous donor showed
a marked decrease. The donor displaying the marked
decrease inCD158b1 cells was the samedonor that dis-
played a marked increase in CD158a1 cells.DISCUSSION
With potentially increasing use of alloreactive NK
cells in clinical practice, the ability to identify suitable
donors is becoming more important. Our incomplete
knowledge of KIR receptor interaction with HLA
ligands mandates that donor alloreactivity toward the
intended recipient be demonstrated in a functional as-
say. NK cloning and the 51Cr-release assays are time
consuming and beyond the capacity of many transplant
centers. The flow cytometric assay described here is rel-
atively simple to perform, reproducible, and can be
completed in twoweeks.Results obtainedusingpurified
NK cells activated by polyclonal expansion for 12 days
were largely concordant with expectation based on
HLA epitopes. Attempts to perform the assay using
freshly isolatedNKcellsorPBMCcultured for 48hours
in IL-2 were largely unsuccessful, perhaps because the
NK cells were insufficiently activated to kill BLCL tar-
gets efficiently. However, we did not test NK cells that
had been polyclonally expanded for\12 days. There-
fore, it may be possible to further shorten the assay.Twelve days in culture increased the percentage of
NK cells with the potentially alloreactive phenotype in
donors whose HLA type would predict alloreactivity,
but not in other donors. In C21 donors, CD158a1
NK cells tended to increase in number during culture,
whereas theydecreased innumberwhen fromaC22 do-
nor.This is consistentwith recentdata showing that that
C22 feeder cells drive proliferation of alloreactive
CD158a1 cells from C21 donors [18], whereas all
CD158a1 cells from C22 donors should be unrespon-
sive to C22 feeder cells, and therefore would not be ex-
pected to expand. Figure 3D shows that the
disappearance of these cells is almost complete in the
case of CD158a1, 158b2 cells in C1 homozygous
(C22) donors and CD158e1, 158a2, 158b2 cells in
Bw6 (Bw42) homozygous donors. The expansion of
CD158b1 cells in C11 donors was not as consistent as
for CD158a1 cells in C21 donors. This may reflect
the fact that a greater proportion (34%) of random
donors constituting the feeder cell pool would lack the
C2 ligand, thereby supporting proliferation of
CD158a1 cells, than would lack the C1 epitope (19%).
It could also reflect the promiscuity of KIR2DL2 and
KIR2DL3, which permits these receptors to interact
weakly with C2 alleles [11]. Presumably, cloning of
NK cells using pooled feeder cells would result in a sim-
ilar preferential growth of alloreactive clones.
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Figure 6. Twelve-day culture expands the alloreactive subset of NK cells. The percentage of NK cells from 9 donors with various C1, C2 genotypes that
were CD158a1 (A); or CD158a1b2 (C); or CD158b1 (B); or CD158b1,158a2 (D) was estimated before and after 12 days culture with pooled, irra-
diated feeder cells. NK cells expressing CD158a (A,C) tended to increase in number if the NK donor had the relevant C2 ligand (C1/2 donors) and
decrease in number if the donor lacks the relevant C2 ligand (C1/1 donors). The single C2 homozygous donor (C2/2) lacked the KIR2DL1 gene and thus
could not be assessed. A similar, though not as pronounced, effect was seen for NK cells expressing CD158b (B,D).
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rectly estimate the alloreactive subsets of NK cells
[11,19]. However, reliable estimation of functional
alloreactive NK cells cannot be achieved by simply
enumerating cells with a particular KIR phenotype be-
cause, as we have shown, these cells may not be armed.
Similarly, functional assays using class I HLA bare
targets or HLA bare cells transfected with single
HLA alleles cannot be used to accurately estimate
alloreactive NK cells. Such targets will stimulate all
NK cells to express CD107a except those with the
relevant inhibitory KIR, only a subset of which are al-
loreactive. Detection of functionally alloreactive NK
cells requires targets that express all HLA epitopes
for inhibitory KIR except the epitope of interest as
used in our method.
Our results show that the method of analyzing the
flow cytometric data is critically important. We found
a small percentage of NK cells express CD107a in the
presence of a target that expresses all 3 epitopes (C1,
C2, and Bw4). This response must be unrelated to
KIR2DL1, KIR2DL2/3, KIR3DL1, and KIR2DS1,
and is unlikely to represent KIR3DL2 activity, as the
target with all epitopes was also HLA-A3 positive.
This response interferes with the detection of C1,C2, or Bw4-dependent allo-responses unless it is min-
imized by restricting the analysis to only thoseNKcells
expressing the inhibitory KIR relevant to the missing
epitope. In the case of KIR2DL1 and KIR2DL2/3-
mediated alloreactivity, we found it necessary only
to gate out cells coexpressing these receptors, whereas
in the case of KIR3DL1-mediated alloreactivity, we
found it necessary to gate out cells coexpressing either
KIR2DL1 and/or KIR2DL2/3 with KIR3DL1. After
focusing on the relevant NK subset, it was found that
the number of these cells that expressed CD107a in
the presence of a target lacking the appropriate epitope,
expressed as a percentage of all NK cells, correlated
well with predictions of alloreactivity based on the
missing ligandmodel.Moreover, the frequencyof allor-
eactive cells as a percentage of all NK cells correlates
well with the frequency reported by NK cloning and
51Cr-release. For example, in the CD107a assay, we
found C2-, C1-, and Bw4-dependent NK cells to be
present at an average frequency of 6%, 10%, and 2%,
which is similar to the frequencies reported by NK
cloning (9%, 5%, 3%, respectively) [14].
We [8] and others [17] have recently reported that
HLA-B13, despite reacting with anti-Bw4 antisera, is
not a ligand for KIR3DL1. The inability of NK cells
190 Biol Blood Marrow Transplant 16:179-191, 2010D. De Santis et al.inHLA-B13-positive donors to express CD107a in the
presence of Bw4- targets shown in our study is consis-
tent with the earlier reports. We [8] and others
[17,20,21] have also reported that the Bw41 HLA-A
alleles, HLA-A24, A32, and to a lesser extent, HLA-
A23, are ligands forKIR3DL1, and in our earlier study,
we provided evidence that HLA-A24 can also induce
arming of KIR3DL1-dependent NK cells [8]. In our
current study, it was therefore surprising to find one
individual, in whom HLA-A24 was the only Bw41
allele, but who had very low numbers of KIR3DL1-
dependent NK cells. Thus, although HLA-A24 in-
hibits cytotoxicity, it may not always arm significant
numbers of NK cells for Bw4-dependent cytotoxicity.
Further studies are required to clarify this point.
Although the frequency of Bw4-dependent NK cells
was very low in 3 of the 4 donors who had HLA-B13
or HLA-A24 as their only Bw41 alleles, the frequency
was intermediate (0.4%-0.9%) between that of donors
with other Bw41 alleles and those lacking Bw4 alto-
gether, suggesting the flow cytometric assay can detect
alloreactive NK cells present at frequencies\1%. It is
not clear whether such a low frequency of alloreactive
clones would be efficacious in HSCTs.
In two individuals, the absence of HLA-C-medi-
ated alloreactivity could not be explained by our cur-
rent understanding of rules governing alloreactivity.
One of these individuals, whose NK cells failed to
express CD107a in response to a C22 target, was ho-
mozygous for KIR2DL1*004, suggesting that
KIR2DL1*004 may not interact with C2, and there-
fore does not arm NK cells expressing this as the
only inhibitory receptor. This is consistent with the re-
cent report that this allele only weakly armsNK cells in
C21 individuals as assessed by their ability to secrete
IFNg in response to class I bare 721.221 targets [17].
There are several reports implying that KIR2DL2
and KIR2DL3 distinguish poorly between the C1
and C2 epitopes [9-12]. KIR2DL3-Fc and
KIR2DL2-Fc fusion proteins have been shown to
bind almost equally to both C1 and C2 alleles [10]. It
has even been suggested that KIR2DL2/31 NK cells
generally require coexpression of KIR2DS1 tomediate
cytotoxicity toward C12 (C2/C2) targets [11,12].
Chewning et al. [12], using polyclonal NK cells, re-
ported that the alloresponse to missing self when C1
is a self-epitope, is rarely observed in NK donors lack-
ing KIR2DS1. Pende et al. [11] also concluded that
KIR2DL2/31NK cells can barely distinguish between
C11 or C21 target cells and their alloreactivity is,
in most cases, dependent on the coexpression of
KIR2DS1. In the 51chromium-release assay employed
by Chewning et al. [12], a significant alloresponse was
interpreted as cytotoxicity significantly above back-
ground levels.However, therewas a considerable back-
ground cytotoxicity in their system and, as we have
shown, in polyclonal systems, alloresponses can be hid-den among the background responses unless the analy-
sis is restricted to those NK cells with a phenotype
relevant to the missing ligand. Using this approach,
we found alloresponses to C12 (C2/C2) targets (but
not C22 targets) mediated by KIR2DL2/
31,KIR2DS12 NK cells in all but one C11 donor.
Such responses were not observed in C12 donors.
Thus, as assessed by our CD107a assay, KIR2DL2/3-
dependent NK cells are present in almost all C11 do-
nors and demonstrate functional distinction between
C1 andC2 epitopes without the need for KIR2DS1 ex-
pression. In the study by Pende et al. [11], in one post-
transplant patient, the majority of polyclonal NK cells
expressing only KIR2DL2/3 (and not KIR2DS1) were
unable to kill C12 targets (or C22 targets), indicating
that such cells are not always alloreactive. However,
in the same patient, cytotoxic KIR2DL2/31NKclones
that did not expressKIR2DS1, but did discriminate be-
tweenC11 andC21 targets, were identified. Our study
does not exclude the possibility thatKIR2DS11donors
have KIR2DL2/31,KIR2DS11 cells, in addition to
KIR2DL2/31,KIR2DS12 cells, that lyse C12 (and
thus C21) targets. Thus, among C1 homozygous do-
nors, thosewithKIR2DS1maywell have a greater total
alloresponse to C12 targets than those without
KIR2DS1. However, it is clear from our data that
KIR2DS1 is not necessary for a KIR2DL2/3-mediated
alloresponse.
Similar frequencies of alloreactive NK cells were
achieved in different ways in different donors. For exam-
ple, the single individual who was homozygous for Bw4
had relatively few (8%) KIR3DL1-positive NK cells
compared to the Bw4 heterozygous donors (range:
15%-65%), a finding previously noted [22]. However,
in the Bw4 homozygote, a relatively large proportion
(30%) of the KIR3DL11 NK cells were Bw4-depen-
dent, resulting in 3% of all NK cells being Bw4-depen-
dent. In contrast, the Bw4 heterozygous individuals,
although they had a higher percentage of KIR3DL11
cells, had a comparatively smaller proportion of these
cells thatwereBw4-dependent, resulting in a similarpro-
portion (2%-7%) of all NK cells being Bw4-dependent.
Therapeutic approaches employing alloreactive NK
cells hold considerable promise for diseases like acute
myelogenous leukemia (AML).However,despiteour im-
proving knowledge of the rules governing alloreactivity,
there is a continuing need for a functional assay of allor-
eactivity. The CD107a assay described here is simple,
robust, and avoids the need for expensive and time-
consuming cloning. In addition, it has proved useful in
the dissection of the rules governing NK alloreactivity.ACKNOWLEDGMENTS
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